Update on Alternative Dosing Strategies for HIV Pre-Exposure Prophylaxis (PrEP)
Sharon Mannheimer, MD
Assistant Professor of Clinical Medicine, Columbia College of Physicians & Surgeons
Faculty Member, Department of Epidemiology, Mailman School of Public Health
Chief of the Division of Infectious Diseases, Harlem Hospital, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2015. All rights reserved.
Dr. Mannheimer’s career in Infectious Diseases has focused on HIV, including clinical care of HIV-infected patients, research on adherence to HIV therapy, and also research on HIV prevention. Dr. Mannheimer helps oversee HIV Services at Harlem Hospital including several Ryan White-funded programs, which provide primary care and other supportive HIV services for residents of Harlem and neighboring communities. She is currently involved in conducting HIV prevention research as the Site Leader of the NIH-funded Harlem Prevention Center Clinical Research Site, located in Harlem and part of ICAP in Columbia’s Mailman School of Public Health. She was the Site Principal Investigator of the ADAPT Study, an HIV Prevention Trials Network study assessing dosing strategies for pre-exposure prophylaxis (PrEP) medication to prevent HIV infection among at risk HIV negative individuals in New York City. She also previously served as member of the Priority Setting and Resource Allocation Committee of the HIV Health and Human Services Planning Council of New York City, and was a past elected member of the New York State Medical Care Criteria Committee, which develops New York State HIV clinical practice guidelines HIV-infected adults.
At the completion of this educational session, learners will:
- Become familiar with the findings of the IPERGAY and ADAPT studies of intermittent PrEP.
-
- Learn the main side effects of PrEP.
- Understand common barriers to PrEP adherence.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
